Erlotinib hydrochloride

Nature Reviews Drug Discovery

Volumn 4, Issue 1, 2005, Pages 13-14

  Dowell, Jonathan ^a   Minna, John D ^a   Kirkpatrick, Peter ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG INDICATION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG NON SMALL CELL CANCER; NOTE; PRIORITY JOURNAL; TREATMENT FAILURE; UNITED STATES;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; EXPERT TESTIMONY; HUMANS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 12144250589     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1612     Document Type: Note

References (14)

1. Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4-S66 (2001).
2. Cersosimo, R. J. Lung cancer: a review. Am. J. Health Syst. Pharm. 59, 611-642 (2002).
3. Dancey, J. & Sausville, E. A. Issues and progress with protein kinase inhibitors for the treatment of cancer. Nature Rev. Drug Discov. 2, 296-313 (2003).
4. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127-137 (2001).
5. Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist 7 (S4), 2-8 (2002).
6. Salomon, D. S. et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol Hematol. 19, 183-232 (1995).
7. Moyer, J. D. et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57, 4838-4848 (1997).
8. Pollack, V. A. et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291 739-748 (1999).
9. FDA label information [online], (2004).
10. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl J. Med. 350, 2129-2139 (2004).
11. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
12. Shigematsu, H. et al. Clinical and biological features of epidermal growth factor receptor mutations in lung cancers. J. Natl Cancer Inst. (in the press).
13. Sandler, A. et al. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small call lung cancer. J. Clin. Oncol. 22, 14S (2004).
14. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and edotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004).